ArticleCancer management and research2021
MiR-129-5p Suppresses Cell Proliferation of Human Osteosarcoma Cancer by Down-Regulating LncRNA Lnc712.
Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Multi-omics profiling identifies ESM1 as a key mediator of immunoevasion through the SPP1 pathway in bladder cancer.Scientific reports · 2025Article
- LncRNA XIST promotes bladder cancer progression by modulating miR-129-5p/TNFSF10 axis.Discover oncology · 2024Article
- Machine learning and experimental validation to construct a metastasis-related gene signature and ceRNA network for predicting osteosarcoma prognosis.Journal of orthopaedic surgery and research · 2022Article
- MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF.Cancer cell international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLnc712 has been characterized as an oncogenic lncRNA in breast cancer. This study aimed to investigate the role of Lnc712 in osteosarcoma (OS).
methodsOS and paired non-tumor tissues were collected from 58 OS patients. Expression of Lnc712 and miR-129-5p in paired tissue samples was determined by RT-qPCR. Lnc712 and miR-129-5p expression was achieved in OS cells to study the interaction between them. Cell proliferation was analyzed by CCK-8 assay.
resultsLnc712 was upregulated in OS and was inversely correlated with miR-129-5p. In OS cells, Lnc712 overexpression failed to significantly affect miR-129-5p, while miR-129-5p overexpression led to downregulated Lnc712. Cell proliferation showed that Lnc712 overexpression resulted in increased cell proliferation rate. MiR-129-5p overexpression played an opposite role and reversed the effect of Lnc712 overexpression. DISCUSSION: MiR-129-5p may suppress cell proliferation of OS by down-regulating Lnc712.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.